{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:56:20Z","timestamp":1780581380421,"version":"3.54.1"},"reference-count":141,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 NS100611"],"award-info":[{"award-number":["U01 NS100611"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1053\/j.semnuclmed.2020.12.003","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T16:17:13Z","timestamp":1610295433000},"page":"275-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Molecular Imaging of Extrapyramidal Movement Disorders With Dementia: The 4R Tauopathies"],"prefix":"10.1053","volume":"51","author":[{"given":"Kirk A.","family":"Frey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0001","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ana.410160303","article-title":"Epidemiology of Parkinsonism: Incidence, classification, and mortality","volume":"16","author":"Rajput","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0002","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00019052-199908000-00011","article-title":"Recent advances in atypical parkinsonian disorders","volume":"12","author":"Litvan","year":"1999","journal-title":"Curr Opin Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0003","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033118","article-title":"Clinical neurology and epidemiology of the major neurodegenerative diseases","volume":"10","author":"Erkkinen","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0004","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/j.semnuclmed.2020.12.002","article-title":"Molecular imaging of dementia with Lewy Bodies and frontotemporal lobar degeneration","volume":"51","author":"Duignan","year":"2020","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0005","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1750-3639.1998.tb00159.x","article-title":"Corticobasal ganglionic degeneration and progressive supranuclear palsy presenting with cognitive decline","volume":"8","author":"Bergeron","year":"1998","journal-title":"Brain Pathol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0006","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000077155","article-title":"Relationship between frontotemporal dementia and corticobasal degeneration\/progressive supranuclear palsy","volume":"17","author":"Kertesz","year":"2004","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0007","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0008","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.parkreldis.2014.04.019","article-title":"Diagnostic accuracy of Parkinsonism syndromes by general neurologists","volume":"20","author":"Joutsa","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0009","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1212\/WNL.0000000000002350","article-title":"Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis","volume":"86","author":"Rizzo","year":"2016","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0010","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1212\/WNL.0000000000000641","article-title":"Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study","volume":"83","author":"Adler","year":"2014","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0011","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/brain\/awf080","article-title":"The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service","volume":"125","author":"Hughes","year":"2002","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0012","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/mds.10680","article-title":"Accuracy of clinical diagnosis of progressive supranuclear palsy","volume":"19","author":"Osaki","year":"2004","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0013","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00415-017-8644-3","article-title":"Corticobasal degeneration: Key emerging issues","volume":"265","author":"Ali","year":"2018","journal-title":"J Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0014","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1468-1331.2008.02513.x","article-title":"Tauopathies with Parkinsonism: Clinical spectrum, neuropathologic basis, biological markers, and treatment options","volume":"16","author":"Ludolph","year":"2009","journal-title":"Eurn J Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0015","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/archneur.1964.00460160003001","article-title":"Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia","volume":"10","author":"Steele","year":"1964","journal-title":"Arch Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.47.1.1","article-title":"Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop","volume":"47","author":"Litvan","year":"1996","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0017","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archneur.56.1.33","article-title":"Diagnostic criteria for Parkinson's disease","volume":"56","author":"Gelb","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0018","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1212\/01.wnl.0000343004.98599.45","article-title":"Sensitivity of current criteria for the diagnosis of behavioral variant frontotemporal dementia","volume":"72","author":"Piguet","year":"2009","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0019","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0020","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","article-title":"Advances in progressive supranuclear palsy: New diagnostic criteria, biomarkers, and therapeutic approaches","volume":"16","author":"Boxer","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0021","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.parkreldis.2020.04.014","article-title":"Progressive supranuclear palsy: Advances in diagnosis and management","volume":"73","author":"Coughlin","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0022","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/brain\/awn065","article-title":"Clinical outcomes of progressive supranuclear palsy and multiple system atrophy","volume":"131","author":"O'Sullivan","year":"2008","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0023","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/archneur.1968.00470310034003","article-title":"Corticodentatonigral degeneration with neuronal achromasia","volume":"18","author":"Rebeiz","year":"1968","journal-title":"Arch Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0024","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/brain\/112.5.1171","article-title":"Corticobasal degeneration","volume":"112","author":"Gibb","year":"1989","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ana.22424","article-title":"Clinicopathological correlations in corticobasal degeneration","volume":"70","author":"Lee","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0026","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0027","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/jnnp-2013-307035","article-title":"Validation of the new consensus criteria for the diagnosis of corticobasal degeneration","volume":"85","author":"Alexander","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0028","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp-2011-300875","article-title":"Diagnostic criteria for corticobasal syndrome: A comparative study","volume":"83","author":"Mathew","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0029","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat Rev Neurosci"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0030","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1750-3639.1999.tb00550.x","article-title":"Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease","volume":"9","author":"Buee","year":"1999","journal-title":"Brain Pathol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0031","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0165-0173(00)00019-9","article-title":"Tau protein isoforms, phosphorylation and role in neurodegenerative disorders","volume":"33","author":"Buee","year":"2000","journal-title":"Brain Res Rev"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0032","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00019052-200008000-00002","article-title":"Tau pathology: A marker of neurodegenerative disorders","volume":"13","author":"Delacourte","year":"2000","journal-title":"Curr Opin Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0033","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s004010000283","article-title":"Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, corticobasal degeneration and progressive supranuclear palsy","volume":"101","author":"Arai","year":"2001","journal-title":"Acta Neuropathol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0034","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2217\/fnl.12.34","article-title":"The challenges of tau imaging","volume":"7","author":"Villemagne","year":"2012","journal-title":"Future Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0035","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s12031-011-9589-0","article-title":"Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau)","volume":"45","author":"Dickson","year":"2011","journal-title":"J Mol Neurosci"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0036","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1212\/WNL.44.11.2015","article-title":"Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy)","volume":"44","author":"Hauw","year":"1994","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0037","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009258","article-title":"Parkinson's disease and Parkinsonism: Neuropathology","volume":"2","author":"Dickson","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0038","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1440-1789.2003.00543.x","article-title":"Pathological heterogeneity in progressive supranuclear palsy and corticobasal degeneration","volume":"24","author":"Wakabayashi","year":"2004","journal-title":"Neuropathology"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0039","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/brain\/awm104","article-title":"Pathological tau burden and distribution distinguishes progressive supranuclear palsy-Parkinsonism from Richardson's syndrome","volume":"130","author":"Williams","year":"2007","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0040","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/WCO.0b013e32833be924","article-title":"Neuropathology of variants of progressive supranuclear palsy","volume":"23","author":"Dickson","year":"2010","journal-title":"Curr Opin Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0041","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/mds.27198","article-title":"Cognitive impairment in progressive supranuclear palsy is associated with tau burden","volume":"32","author":"Koga","year":"2017","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0042","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jnen\/61.11.935","article-title":"Office of rare diseases neuropathologic criteria for corticobasal degeneration","volume":"61","author":"Dickson","year":"2002","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0043","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrneurol.2011.43","article-title":"Corticobasal degeneration: A pathologically distinct 4R tauopathy","volume":"7","author":"Kouri","year":"2011","journal-title":"Nat Rev Neurol"},{"issue":"suppl 2","key":"10.1053\/j.semnuclmed.2020.12.003_bib0044","doi-asserted-by":"crossref","first-page":"II6","DOI":"10.1007\/BF03161076","article-title":"Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration","volume":"246","author":"Dickson","year":"1999","journal-title":"J Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0045","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s004010050911","article-title":"Astrocytic plaques and tufts of abnormal fibers do not coexist in corticobasal degeneration and progressive supranuclear palsy","volume":"96","author":"Komori","year":"1998","journal-title":"Acta Neuropathol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0046","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/brain\/awq123","article-title":"Does corticobasal degeneration exist? A clinicopathological re-evaluation","volume":"133","author":"Ling","year":"2010","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0047","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1093\/brain\/aww256","article-title":"Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology","volume":"139","author":"Ling","year":"2016","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0048","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ana.410240308","article-title":"Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography","volume":"24","author":"Foster","year":"1988","journal-title":"Ann Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0049","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/archneur.1990.00530070035009","article-title":"Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations","volume":"47","author":"Blin","year":"1990","journal-title":"Arch Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0050","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.parkreldis.2014.05.013","article-title":"Functional correlates of vertical gaze palsy and other ocular motor deficits in PSP: An FDG-PET study","volume":"20","author":"Amtage","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0051","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s00415-014-7256-4","article-title":"FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants","volume":"261","author":"Zalewski","year":"2014","journal-title":"J Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0052","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/jcbfm.1994.99","article-title":"The metabolic topography of Parkinsonism","volume":"14","author":"Eidelberg","year":"1994","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0053","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jnnp.54.10.856","article-title":"The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography","volume":"54","author":"Eidelberg","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0054","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/mds.870070409","article-title":"Corticobasal degeneration: Decreased and asymmetrical glucose consumption as studied with PET","volume":"7","author":"Blin","year":"1992","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0055","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s004150050534","article-title":"Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration","volume":"246","author":"Laureys","year":"1999","journal-title":"J Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0056","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/1531-8257(200009)15:5<894::AID-MDS1021>3.0.CO;2-S","article-title":"Voxel-based distribution of metabolic impairment in corticobasal degeneration","volume":"15","author":"Garraux","year":"2000","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0057","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0720-048X(03)00214-6","article-title":"Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET","volume":"51","author":"Juh","year":"2004","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0058","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/S1353-8020(11)70020-7","article-title":"[18F]-FDG PET study on the idiopathic Parkinson's disease from several parkinsonian-plus syndromes","volume":"18","author":"Zhao","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0059","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/01616412.2017.1312211","article-title":"The utility of FDG-PET in the differential diagnosis of Parkinsonism","volume":"39","author":"Brajkovic","year":"2017","journal-title":"Neurol Res"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0060","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/ene.13269","article-title":"Evaluation of an optimized [18 F]fluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical parkinsonian disorders","volume":"24","author":"Caminiti","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0061","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3389\/fneur.2018.00483","article-title":"Clinical routine FDG-PET imaging of suspected progressive supranuclear palsy and corticobasal degeneration: A gatekeeper for subsequent tau-PET imaging?","volume":"9","author":"Beyer","year":"2018","journal-title":"Front Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0062","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11910-019-0966-3","article-title":"Recent advancement and clinical implications of 18FDG-PET in Parkinson's disease, atypical Parkinsonisms, and other movement disorders","volume":"19","author":"Peralta","year":"2019","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0063","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2967\/jnumed.115.159822","article-title":"18F-FDG PET is an early predictor of overall survival in suspected atypical Parkinsonism","volume":"56","author":"Hellwig","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0064","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.2967\/jnumed.116.186403","article-title":"18F-FDG PET in Parkinsonism: Differential diagnosis and evaluation of cognitive impairment","volume":"58","author":"Meyer","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0065","doi-asserted-by":"crossref","first-page":"e1121","DOI":"10.1212\/WNL.0000000000007038","article-title":"FDG-PET patterns associated with underlying pathology in corticobasal syndrome","volume":"92","author":"Pardini","year":"2019","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0066","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.neuroimage.2005.03.012","article-title":"FDG PET in the differential diagnosis of parkinsonian disorders","volume":"26","author":"Eckert","year":"2005","journal-title":"Neuroimage"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0067","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.neuroimage.2008.12.063","article-title":"Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features","volume":"45","author":"Spetsieris","year":"2009","journal-title":"Neuroimage"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0068","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1474-4422(10)70002-8","article-title":"Differential diagnosis of Parkinsonism: A metabolic imaging study using pattern analysis","volume":"9","author":"Tang","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0069","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/mds.25361","article-title":"Validation of parkinsonian disease-related metabolic brain patterns","volume":"28","author":"Teune","year":"2013","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0070","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00234-012-1132-7","article-title":"Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography","volume":"55","author":"Tripathi","year":"2013","journal-title":"Neuroradiology"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0071","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.nicl.2013.06.004","article-title":"Multiclass classification of FDG PET scans for the distinction between Parkinson's disease and atypical parkinsonian syndromes","volume":"2","author":"Garraux","year":"2013","journal-title":"Neuroimage Clin"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0072","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1093\/brain\/awu256","article-title":"A disease-specific metabolic brain network associated with corticobasal degeneration","volume":"137","author":"Niethammer","year":"2014","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0073","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1055\/s-0034-1381733","article-title":"The utility of neuroimaging in the differential diagnosis of parkinsonian syndromes","volume":"34","author":"Holtbernd","year":"2014","journal-title":"Semin Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0074","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2967\/jnumed.115.161992","article-title":"Automated differential diagnosis of early Parkinsonism using metabolic brain networks: A validation study","volume":"57","author":"Tripathi","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0075","doi-asserted-by":"crossref","DOI":"10.1002\/mds.28217","article-title":"Multicenter validation of metabolic abnormalities related to PSP according to the MDS-PSP criteria","author":"Mart\u00ed-Andr\u00e9s","year":"2020","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0076","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/WCO.0000000000000106","article-title":"Update on SPECT and PET in Parkinsonism\u2014Part 1: Imaging for differential diagnosis","volume":"27","author":"Meyer","year":"2014","journal-title":"Curr Opin Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0077","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.semnuclmed.2018.07.006","article-title":"PET imaging in movement disorders","volume":"8","author":"Maiti","year":"2018","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0078","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2967\/jnumed.108.059998","article-title":"Imaging approaches to Parkinson disease","volume":"51","author":"Brooks","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0079","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/305137a0","article-title":"Dopamine visualized in the basal ganglia of living man","volume":"305","author":"Garnett","year":"1983","journal-title":"Nature"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0080","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/archneur.1990.00530120034007","article-title":"The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease","volume":"47","author":"Leenders","year":"1990","journal-title":"Arch Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0081","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ana.410340331","article-title":"Positron emission tomographic imaging of the dopamine transporter with \"C-WIN 35,428 reveals marked declines in mild Parkinson's disease","volume":"34","author":"Frost","year":"1993","journal-title":"Ann Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0082","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ana.410400609","article-title":"Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging","volume":"40","author":"Frey","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0083","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ana.410280412","article-title":"Differing patterns of striatal F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy","volume":"28","author":"Brooks","year":"1990","journal-title":"Ann Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0084","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10072-003-0103-5","article-title":"123I-Ioflupane\/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy","volume":"24","author":"Antonini","year":"2003","journal-title":"Neurol Sci"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0085","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2967\/jnumed.112.105379","article-title":"Nigrostriatal dopamine terminal imaging with dopamine transporter SPECT: An update","volume":"54","author":"Tatsch","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0086","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.arr.2015.12.009","article-title":"Molecular imaging of dopamine transporters","volume":"30","author":"Brooks","year":"2016","journal-title":"Ageing Res Rev"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0087","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1177\/0271678X16637880","article-title":"Metabolic network expression in Parkinsonism: Clinical and dopaminergic correlations","volume":"37","author":"Ko","year":"2017","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0088","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00702-004-0208-x","article-title":"Combined 123I-FP-CIT and 123IIBZM SPECT for the diagnosis of parkinsonian syndromes: Study on 72 patients","volume":"112","author":"Plotkin","year":"2005","journal-title":"J Neural Transm"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0089","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000115640","article-title":"Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes","volume":"59","author":"Vlaar","year":"2008","journal-title":"Eur Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0090","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/mds.21004","article-title":"Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration","volume":"21","author":"Klaffke","year":"2006","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0091","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000443667","article-title":"FP-CIT and IBZM-SPECT in corticobasal syndrome: Results from a clinical follow-up study","volume":"16","author":"Hammesfahr","year":"2016","journal-title":"Neurodegen Dis"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0092","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1212\/WNL.0b013e31826c1b0a","article-title":"[\u00b9\u2078F]FDG-PET is superior to [\u00b9\u00b2\u00b3I]IBZM-SPECT for the differential diagnosis of Parkinsonism","volume":"79","author":"Hellwig","year":"2012","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0093","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/S0140-6736(96)09124-6","article-title":"Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease","volume":"349","author":"Iyo","year":"1997","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0094","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1212\/WNL.52.4.691","article-title":"In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease","volume":"52","author":"Kuhl","year":"1999","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0095","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1212\/WNL.0b013e3181dc1a55","article-title":"Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes","volume":"74","author":"Gilman","year":"2010","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0096","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/1531-8249(199907)46:1<62::AID-ANA10>3.0.CO;2-P","article-title":"Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy","volume":"46","author":"Shinotoh","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0097","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/brain\/awq120","article-title":"Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia","volume":"133","author":"Hirano","year":"2010","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0098","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0306-4522(91)90197-V","article-title":"Differential vulnerability of cholinergic projections to the mediodorsal nucleus of the thalamus in senile dementia of Alzheimer type and progressive supranuclear palsy","volume":"41","author":"Brandel","year":"1991","journal-title":"Neuroscience"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0099","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00401-002-0621-x","article-title":"Cholinergic neuronal loss in the basal forebrain and mesopontine tegmentum of progressive supranuclear palsy and corticobasal degeneration","volume":"105","author":"Kasashima","year":"2003","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0100","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1212\/WNL.58.7.1013","article-title":"Cholinergic vesicular transporters in progressive supranuclear palsy","volume":"58","author":"Suzuki","year":"2002","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0101","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/j.semnuclmed.2017.06.003","article-title":"Small-molecule PET tracers for imaging proteinopathies","volume":"47","author":"Mathis","year":"2017","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0102","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0103","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2967\/jnumed.110.076315","article-title":"Brain amyloid imaging","volume":"52","author":"Rowe","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0104","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0105","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jama.2015.4669","article-title":"Prevalence of amyloid PET positivity in dementia syndromes: A meta-analysis","volume":"313","author":"Ossenkoppele","year":"2015","journal-title":"JAMA"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0106","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2967\/jnumed.113.136069","article-title":"Molecular imaging insights into neurodegeneration: Focus on tau PET radiotracers","volume":"55","author":"Shah","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0107","first-page":"S254","article-title":"In vivo tau imaging: obstacles and progress","volume":"10","author":"Villemange","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0108","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1474-4422(14)70252-2","article-title":"Tau imaging: Early progress and future directions","volume":"14","author":"Villemagne","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0109","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s00259-015-3231-2","article-title":"Tau imaging in neurodegenerative diseases","volume":"43","author":"Dani","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0110","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00019442-200201000-00004","article-title":"Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease","volume":"10","author":"Shoghi-Jadid","year":"2002","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0111","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3233\/JAD-122059","article-title":"Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807","volume":"34","author":"Chien","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0112","first-page":"748","article-title":"Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition","volume":"140","author":"Pontecorvo","year":"2017","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0113","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/mds.26834","article-title":"[18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy","volume":"32","author":"Whitwell","year":"2017","journal-title":"Move Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0114","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ana.25060","article-title":"18F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study","volume":"82","author":"Schonhaut","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0115","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00401-016-1650-1","article-title":"Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy","volume":"133","author":"Smith","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0116","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/mds.26813","article-title":"Increased basal ganglia binding of 18F-AV-1451 in patients with progressive supranuclear palsy","volume":"32","author":"Smith","year":"2017","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0117","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/mds.26844","article-title":"Subcortical 18F-AV-1451 binding patterns in progressive supranuclear palsy","volume":"32","author":"Cho","year":"2017","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0118","first-page":"781","article-title":"18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy","volume":"140","author":"Passamonti","year":"2017","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0119","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1177\/0271678X16683695","article-title":"Positron emission tomography imaging of tau pathology in progressive supranuclear palsy","volume":"37","author":"Coakeley","year":"2017","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0120","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ana.24844","article-title":"Pathological correlations of [F-18]-AV-1451 imaging in non-Alzheimer tauopathies","volume":"81","author":"Marquie","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0121","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00429-017-1507-y","article-title":"[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP","volume":"223","author":"Coakeley","year":"2018","journal-title":"Brain Struct Funct"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0122","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/brain\/aww098","article-title":"In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET","volume":"139","author":"Hansen","year":"2016","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0123","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1212\/WNL.0000000000004264","article-title":"In vivo retention of 18F-AV-1451 in corticobasal syndrome","volume":"89","author":"Smith","year":"2017","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0124","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/ana.24517","article-title":"Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue","volume":"78","author":"Marquie","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0125","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jalz.2016.01.003","article-title":"Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias","volume":"12","author":"Sander","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0126","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","article-title":"An autoradiographic evaluation of AV-1451 Tau PET in dementia","volume":"4","author":"Lowe","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0127","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mds.27271","article-title":"The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases","volume":"33","author":"Vermeiren","year":"2018","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0128","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11307-017-1143-1","article-title":"MAO-B inhibitors do not block in vivo flortaucipir([18F]-AV-1451) binding","volume":"20","author":"Hansen","year":"2018","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0129","doi-asserted-by":"crossref","first-page":"10857","DOI":"10.1523\/JNEUROSCI.1738-05.2005","article-title":"Quinoline and benzimidazole derivatives: Candidate probes for in vivo imaging of tau pathology in Alzheimer's disease","volume":"25","author":"Okamura","year":"2005","journal-title":"J Neurosci"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0130","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2967\/jnumed.115.164848","article-title":"18F-THK5351: A novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease","volume":"57","author":"Harada","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0131","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40478-018-0556-7","article-title":"Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy","volume":"6","author":"Ishiki","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0132","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1212\/WNL.0000000000003375","article-title":"In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET","volume":"87","author":"Kikuchi","year":"2016","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0133","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13195-017-0253-y","article-title":"Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain","volume":"9","author":"Ng","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0134","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2019.102091","article-title":"Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy","volume":"24","author":"Ng","year":"2019","journal-title":"Neuroimage Clin"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0135","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fnagi.2019.00249","article-title":"PET imaging of astrogliosis and tau facilitates diagnosis of parkinsonian syndromes","volume":"11","author":"Sch\u00f6necker","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0136","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","article-title":"Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls","volume":"79","author":"Maruyama","year":"2013","journal-title":"Neuron"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0137","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/mds.27643","article-title":"In vivo binding of a tau imaging probe, [11C]PBB3, in patients with progressive supranuclear palsy","volume":"34","author":"Endo","year":"2019","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0138","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/mds.27029","article-title":"PBB3 imaging in parkinsonian disorders: Evidence for binding to tau and other proteins","volume":"32","author":"Perez-Soriano","year":"2017","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0139","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/mds.27013","article-title":"Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to alpha-synuclein pathology","volume":"32","author":"Koga","year":"2017","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0140","first-page":"764","article-title":"Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies","volume":"140","author":"Ono","year":"2017","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2020.12.003_bib0141","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-017-0325-z","article-title":"Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains","volume":"9","author":"Lemoine","year":"2017","journal-title":"Alzheimers Res Ther"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299820301264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299820301264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:38:54Z","timestamp":1757543934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299820301264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":141,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0001299820301264"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2020.12.003","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Imaging of Extrapyramidal Movement Disorders With Dementia: The 4R Tauopathies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2020.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}